Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 5 of 5
  • Item
    Thumbnail Image
    Unproven medical devices and cancer therapy: big claims but no evidence.
    Mac Manus, M (Department of Biomedical Imaging, University of Malaya, Malaysia, 2008-07)
  • Item
    Thumbnail Image
    Conformal radiotherapy and molecular imaging: complementary technologies in cancer therapy.
    Mac Manus, M (Department of Biomedical Imaging, University of Malaya, Malaysia, 2006-01)
  • Item
    Thumbnail Image
    Improving radiation therapy for non-small cell lung cancer: molecular imaging and a team-based approach.
    Everitt, S ; Mac Manus, M (Department of Biomedical Imaging, University of Malaya, Malaysia, 2007-01)
    The successful integration of molecular imaging and radiation therapy has been shown to significantly impact the management of patients with non-small cell lung cancer (NSCLC). The collaboration of multidisciplinary team members, including radiation oncologists, radiation therapists, nuclear medicine physicians and physicists, has enabled PET/CT to be utilised for routine use throughout the radiotherapy treatment trajectory. Applications include disease diagnosis and staging, target volume definition for radiation therapy and monitoring tumour response to treatment. Not only has the adoption of this technology demonstrated benefits for our current patients, it is also opening doors for significant research in the future.
  • Item
    Thumbnail Image
    Incorporating PET information in radiation therapy planning.
    Macmanus, M ; Leong, T (Department of Biomedical Imaging, University of Malaya, Malaysia, 2007-01)
    PET scanning, because of its impressive sensitivity and accuracy, is being incorporated into the standard staging workup for many cancers. These include lung cancer, lymphomas, head and neck cancers, and oesophageal cancers. PET often provides incremental information about the patient's disease status, adding to the data obtained from structural imaging methods, such as, CT scan or MRI. PET commonly upstages patients into more advanced disease categories. Incorporation of PET information into the radiotherapy planning process has the potential to reduce the risks of geographic miss and can help minimise unnecessary irradiation of normal tissues. The best means of incorporating PET information into radiotherapy planning is uncertain, and considerable effort is being expended in this area of research.
  • Item
    Thumbnail Image
    A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
    Michael, M ; Wirth, A ; Ball, DL ; MacManus, M ; Rischin, D ; Mileshkin, L ; Solomon, B ; McKendrick, J ; Milner, AD (NATURE PUBLISHING GROUP, 2005-09-19)
    The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS